40 related articles for article (PubMed ID: 17432437)
1. Closing in on a cure.
Healy B
US News World Rep; 2006 Oct; 141(15):67. PubMed ID: 17432437
[No Abstract] [Full Text] [Related]
2. Targeting breast cancer stem cells.
Wicha MS
Breast; 2009 Oct; 18 Suppl 3():S56-8. PubMed ID: 19914544
[No Abstract] [Full Text] [Related]
3. FDA approves new drug for specific type of advanced breast cancer.
Mayo Clin Womens Healthsource; 2007 Oct; 11(10):3. PubMed ID: 18418907
[No Abstract] [Full Text] [Related]
4. Lapatinib study supports cancer stem cell hypothesis, encourages industry research.
Schmidt C
J Natl Cancer Inst; 2008 May; 100(10):694-5. PubMed ID: 18477795
[No Abstract] [Full Text] [Related]
5. Biological therapy of breast cancer: recent clinical applications.
Baar J
Curr Opin Investig Drugs; 2007 Dec; 8(12):987-95. PubMed ID: 18058569
[TBL] [Abstract][Full Text] [Related]
6. [Position statement of the (Hungarian) College of Oncology and Radiotherapy regarding the financing of Tyverb (lapatinib) based on individual discretionary compassionate care].
Pikó B;
Magy Onkol; 2009 Mar; 53(1):77-9. PubMed ID: 19318330
[No Abstract] [Full Text] [Related]
7. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib-associated toxicity and practical management recommendations.
Moy B; Goss PE
Oncologist; 2007 Jul; 12(7):756-65. PubMed ID: 17673607
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab: new indication. Adjuvant breast cancer treatment for a minority.
Prescrire Int; 2007 Jun; 16(89):106. PubMed ID: 17582927
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
[TBL] [Abstract][Full Text] [Related]
11. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
Chen FL; Xia W; Spector NL
Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
[TBL] [Abstract][Full Text] [Related]
12. Acute paronychia caused by lapatinib therapy.
Rigopoulos D; Gregoriou S; Belyayeva Y; Larios G; Gkouvi A; Katsambas A
Clin Exp Dermatol; 2009 Jan; 34(1):94-5. PubMed ID: 19076807
[No Abstract] [Full Text] [Related]
13. Ten remarkable years.
Sledge GW
Clin Breast Cancer; 2010 Jun; 10(3):178. PubMed ID: 20497915
[No Abstract] [Full Text] [Related]
14. Cancer stem cells: a step toward the cure.
Boman BM; Wicha MS
J Clin Oncol; 2008 Jun; 26(17):2795-9. PubMed ID: 18539956
[No Abstract] [Full Text] [Related]
15. Lapatinib for inflammatory breast cancer.
Hall PS; Hanby A; Cameron DA
Lancet Oncol; 2009 Jun; 10(6):538-9. PubMed ID: 19482243
[No Abstract] [Full Text] [Related]
16. No cure in sight for the world's drug problem.
Holmes D
Lancet Oncol; 2009 May; 10(5):450. PubMed ID: 19418615
[No Abstract] [Full Text] [Related]
17. Stat bite: Currently approved oncology drugs.
J Natl Cancer Inst; 2007 Mar; 99(5):344. PubMed ID: 17341722
[No Abstract] [Full Text] [Related]
18. Closing in on the unknown enemy.
Gnant M; Dubsky P
Lancet Oncol; 2010 May; 11(5):402-3. PubMed ID: 20434707
[No Abstract] [Full Text] [Related]
19. Down the road for breast cancer.
Mohundro MM; Mohundro BL
Am J Manag Care; 2012 Sep; 18(4 Spec No.):SP181-4. PubMed ID: 23009239
[No Abstract] [Full Text] [Related]
20. Stem cells that kill.
Park A
Time; 2006 Apr; 167(17):50-1. PubMed ID: 16649672
[No Abstract] [Full Text] [Related]
[Next] [New Search]
